ReviewFrontiers in microbiology2017
Antibody Engineering for Pursuing a Healthier Future.
Review in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 150 citations in OpenAlex.
- Rapid Generation of High-Affinity Rabbit Anti-Mouse IgG Monoclonal Antibodies by High-Throughput Single-B-Cell Sorting and Recombinant Expression.Current issues in molecular biology · 2026Article
- Specific Binding Agents for the Molecular Recognition of Biotoxins: Recent Advances and Applications in Forensic Toxicology.Molecules (Basel, Switzerland) · 2026Review
- Functional screening of TCR-like antibodies using STAR-T cell library for cancer immunotherapy.EMBO molecular medicine · 2026Article
- Evaluation of polyclonal antibodies raised in rabbits against dengue NS1 antigen.Scientific reports · 2026Article
- Key directions of fundamental research on bacteriophage Receptor Binding Proteins with applied potential.Frontiers in microbiology · 2026Review
- Development of a differentiating of infected from vaccinated animal (DIVA) ELISA to detect antibodies against Senecavirus A in pigs using two expression systems of non-structural proteins.The veterinary quarterly · 2025Article
- Antibody-oligonucleotide conjugates for spatial proteomics: principles, applications, and challenges.Acta biochimica et biophysica Sinica · 2025Article
- Challenges and Potential of Antibody-Drug Conjugates as Prospective Tuberculosis Therapeutics.Microorganisms · 2025Review
- Haptens Optimization Using Molecular Modeling and Paper-Based Immunosensor for On-Site Detection of Carbendazim in Vegetable Products.Biosensors · 2025Article
- Hinge Truncation to Improve Aggregation Kinetics and Thermal Stability of an Antibody Fab Fragment.Molecular pharmaceutics · 2025Article
- Exploring Experimental and In Silico Approaches for Antibody-Drug Conjugates in Oncology Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Neutralization of the Pandemic Influenza A/H1N1 Virus withAntibodies (Basel, Switzerland) · 2025Article
- A Comprehensive Review of the Mechanisms and Clinical Development of Monoclonal Antibodies in Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- An Inducible Luminescent System to Explore Parkinson's Disease-Associated Genes.International journal of molecular sciences · 2024Article
- Development of an indirect ELISA for detecting Toxoplasma gondii IgG antibodies based on a recombinant TgIMP1 protein.PLoS neglected tropical diseases · 2024Article
- rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.Antibody therapeutics · 2024Article
- Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Identification of Inhibitors of the Disease-Associated Protein Phosphatase Scp1 Using Antibody Mimetic Molecules.International journal of molecular sciences · 2024Article
- Site-Selective Tyrosine Reaction for Antibody-Cell Conjugation and Targeted Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Tetrodotoxin and the state-of-the-art progress of its associated analytical methods.Frontiers in microbiology · 2024Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of infectious pathogens, malignant diseases including autoimmune disorders, and numerous potent toxins. However, these clinical humanized or chimeric murine antibodies have several limitations and complexities. Therefore, to overcome these difficulties, recent advances in genetic engineering techniques and phage display technique have allowed the production of highly specific recombinant antibodies. These engineered antibodies have been constructed in the hunt for novel therapeutic drugs equipped with enhanced immunoprotective abilities, such as engaging immune effector functions, effective development of fusion proteins, efficient tumor and tissue penetration, and high-affinity antibodies directed against conserved targets. Advanced antibody engineering techniques have extensive applications in the fields of immunology, biotechnology, diagnostics, and therapeutic medicines. However, there is limited knowledge regarding dynamic antibody development approaches. Therefore, this review extends beyond our understanding of conventional polyclonal and monoclonal antibodies. Furthermore, recent advances in antibody engineering techniques together with antibody fragments, display technologies, immunomodulation, and broad applications of antibodies are discussed to enhance innovative antibody production in pursuit of a healthier future for humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.